Key result
Weight-based ribavirin during pegylated interferon-alpha therapy increased the likelihood of moderate to severe depressive symptoms compared to standard dose (OR 2.7; 95% CI 1.3-5.6; P<0.01).
Why the study?
Does weight-based ribavirin compared to standard dose ribavirin increase depressive symptoms in HCV-infected patients treated with pegylated IFN alpha-2b?
Population
162 HCV-infected patients
Comparison
Pegylated IFN alpha-2b plus weight-based ribavirin vs Pegylated IFN alpha-2b plus standard dose…
Design
Cohort
Follow-up
24 weeks
Authors
Loading...
May warrant closer depression monitoring with weight-based ribavirin; leaves open causal effects in HCV interferon regimens.
RCT (n=162)
Does weight-based ribavirin compared to standard dose ribavirin increase depressive symptoms in HCV-infected patients treated with pegylated IFN alpha-2b?
Odds Ratio: 2.7 (95% CI 1.3–5.6)
p-value: p=<0.01
Weight-based ribavirin dosing and baseline depression scores predict the development of moderate to severe depressive symptoms during HCV treatment with pegylated interferon-alpha.
Raison et al. (2005) conducted an RCT in Hepatitis C virus (HCV) infection (n=162). Weight-based ribavirin plus pegylated IFN alpha-2b vs. Standard dose ribavirin plus pegylated IFN alpha-2b was evaluated on Development of moderate to severe depressive symptoms (SDS index score ≥ 60) (OR 2.7, 95% CI 1.3-5.6, p=<0.01). Weight-based ribavirin during pegylated interferon-alpha therapy increased the likelihood of moderate to severe depressive symptoms compared to standard dose (OR 2.7; 95% CI 1.3-5.6; P<0.01).
Synapse has enriched one closely related paper. Consider it for comparative context: